Altay Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $37M

  • Investors
  • 13

Altay Therapeutics General Information

Description

Developer of disease-modifying therapies intended to treat neuromuscular diseases and oncology. The company's method targets utilizing novel drug development platforms powered by genetics, AI, and computational biology to treat chronic indications such as rheumatoid arthritis, fibrotic diseases, ulcerative colitis, and liver cancer, enabling researchers to discover small-molecule binding sites within previously undruggable proteins.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States
+1 (650)

Altay Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Altay Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series A1) 14-Oct-2026 $37M Completed Clinical Trials - General
7. Grant 12-May-2025 Completed Clinical Trials - General
6. Later Stage VC 14-Apr-2024 Completed Clinical Trials - General
5. Early Stage VC (Series A) 21-Sep-2022 Completed Clinical Trials - General
4. Grant 01-Jun-2022 Completed Clinical Trials - General
3. Accelerator/Incubator 18-Mar-2020 Completed Startup
2. Accelerator/Incubator 01-Jan-2020 Completed Startup
1. Accelerator/Incubator 07-Aug-2019 Completed Startup
To view Altay Therapeutics’s complete valuation and funding history, request access »

Altay Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 2
Series A 1
Series A 4 4,544,180 $0.000100 8% $0.03 $0.03 1x $0.03 1.37%
Series A 3 54,106,654 $0.000100 8% $0.14 $0.14 1x $0.14 16.3%
To view Altay Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Altay Therapeutics Patents

Altay Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4794785-A1 Carbocyclic and heterocyclic stat3 inhibitor compositions and methods Pending 10-Nov-2023
WO-2025102082-A1 Carbocyclic and heterocyclic stat3 inhibitor compositions and methods Inactive 10-Nov-2023
AU-2024364448-A1 N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders Pending 20-Oct-2023
EP-4795028-A1 N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders Pending 20-Oct-2023
US-20260176256-A1 N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders Pending 20-Oct-2023 C07D401/14
To view Altay Therapeutics’s complete patent history, request access »

Altay Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Altay Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Biogen Corporation Minority
Fountain Health Partners Growth/Expansion Minority
Global BioAccess Fund Venture Capital Minority
HealthCap Venture Capital Minority
Pappas Capital Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Altay Therapeutics FAQs

  • When was Altay Therapeutics founded?

    Altay Therapeutics was founded in 2019.

  • Where is Altay Therapeutics headquartered?

    Altay Therapeutics is headquartered in San Carlos, CA.

  • What is the size of Altay Therapeutics?

    Altay Therapeutics has 6 total employees.

  • What industry is Altay Therapeutics in?

    Altay Therapeutics’s primary industry is Biotechnology.

  • Is Altay Therapeutics a private or public company?

    Altay Therapeutics is a Private company.

  • What is the current valuation of Altay Therapeutics?

    The current valuation of Altay Therapeutics is .

  • What is Altay Therapeutics’s current revenue?

    The current revenue for Altay Therapeutics is .

  • How much funding has Altay Therapeutics raised over time?

    Altay Therapeutics has raised $43.2M.

  • Who are Altay Therapeutics’s investors?

    Biogen, Fountain Health Partners, Global BioAccess Fund, HealthCap, and Pappas Capital are 5 of 13 investors who have invested in Altay Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process